WO2023187460 - HUMAN ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF SPECIFIC AGAINST PD-L1 TO ENHANCE T-CELL FUNCTION
National phase entry is expected:
Publication Number
WO/2023/187460
Publication Date
05.10.2023
International Application No.
PCT/IB2022/056172
International Filing Date
04.07.2022
Title **
[English]
HUMAN ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF SPECIFIC AGAINST PD-L1 TO ENHANCE T-CELL FUNCTION
[French]
ANTICORPS HUMAIN OU FRAGMENT DE LIAISON À L'ANTIGÈNE DE CELUI-CI SPÉCIFIQUE CONTRE PD-L1 POUR AMÉLIORER LA FONCTION DES LYMPHOCYTES T
Applicants **
MABTREE BIOLOGICS AG
Street Kugelweg 11e, Basel
CH-4222 Zwingen, CH
Inventors
ALEXANDER, Ratna Monica
Kugelweg 11e, Zwingen, Basel
CH-4222 Zwingen, CH
Priority Data
202241019848
01.04.2022
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1114 | |
| EPO | Filing, Examination | 5021 | |
| Japan | Filing | 594 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 2710 |
Total: 10014 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention provides human antibody(ies) or antigen binding fragment(s) specific against PD-L1 capable of binding to PD-L1 and block its interaction with programmed death-1 (PD-1) thereby enhancing T-cell function which has applications in treatment of cancer and infectious diseases. The human antibodies or antigen binding fragments specific against PD-L1 comprise of LCDR1 of Seq. ID 1 or Seq. ID 2;LCDR2 of Seq. ID 3; andLCDR3 of Seq. ID 4 or Seq. ID 5; further comprise of HCDR1 of Seq. ID 8;HCDR2 of Seq. ID 9; andHCDR3 of Seq. ID 10 or Seq. ID 11. The present invention also provides human antibodies or antigen binding fragments specific against PD-L1 comprising light chain of Seq. ID 6 and heavy chain of Seq. ID 12, and light chain of Seq. ID 7 and heavy chain of Seq. ID 13.[French]
La présente invention concerne un ou plusieurs anticorps humains ou un ou plusieurs fragments de liaison à l'antigène spécifiques contre PD-L1 capables de se lier à PD-L1 et bloquer son interaction avec la mort programmée-1 (PD-1), ce qui permet d'améliorer la fonction des lymphocytes T qui a des applications dans le traitement du cancer et de maladies infectieuses. Les anticorps humains ou les fragments de liaison à l'antigène spécifiques contre PD-L1 comprennent LCDR1 de Seq. ID 1 ou Seq. ID 2 ; LCDR2 de Seq. ID 3 ; et LCDR3 de Seq. ID 4 ou Seq. ID 5 ; comprennent en outre HCDR1 de Seq. ID 8 ; HCDR2 de Seq. ID 9 ; et HCDR3 de Seq. ID 10 ou Seq. ID 11. La présente invention concerne également des anticorps humains ou des fragments de liaison à l'antigène spécifiques contre PD-L1 comprenant une chaîne légère de Seq. ID 6 et une chaîne lourde de Seq. ID 12, et une chaîne légère de Seq. ID 7 et une chaîne lourde de Seq. ID 13.